RightFit
Not yet recruitingPhase 4

Rocklatan Retinal Perfusion OCT Study

Rocklatan Trial With Optical Coherence Tomography Study of Retinal Perfusion

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
21 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

The main purpose of this study is to learn more about how Rocklatan eye drops affects blood flow in the eye. The secondary purpose is to see if our study devices can detect changes in blood flow before and after instillation of Rocklatan.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Official eligibility criteria

Inclusion Criteria: 1. Patients with both eyes with open angle glaucoma. 2. Abnormal VF (glaucomatous pattern with PSD abnormal at p\<0.05 or GHT outside normal limits) on most recent two clinic visits on chart review 3. Glaucomatous disc abnormality on chart review and confirmed on baseline disc photograph 4. Overall average NFL thickness \> 55 μm measured by Heidelberg Spectralis OCT -Glaucoma Module Premium Edition (chart review), consistent with early glaucoma 5. NFLP-CD deficit (below 5 percentile of normal) in any of the 8 sectors on the initial baseline visit 6. The difference in baseline NFLP-CD between the left and right eye should be less than 5% (% of area). 7. IOP \>= 17 mm Hg on the most recent two clinic visits (chart review) after monotherapy with latanoprost in both eyes. Exclusion Criteria: 1. Best corrected visual acuity worse than 20/30 on chart review of most recent clinic visit 2. Age \< 21 years at baseline 3. Eye disease that could affect VF, NFL thickness, or NFLP (e.g., visually significant cataract, AMD, diabetic retinopathy, and optic neuropathy) at any study visit 4. OCT and OCTA scans not meeting quality criteria at baseline 5. Inability to cooperate with study procedures 6. Inability to commit to the study visits

Study sites (1)

OR